NASDAQ:CVAC CureVac (CVAC) Stock Price, News & Analysis $3.02 +0.06 (+2.03%) (As of 10/4/2024 ET) Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends About CureVac Stock (NASDAQ:CVAC) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get CureVac alerts:Sign Up Key Stats Today's Range$2.96▼$3.0750-Day Range$2.74▼$3.7752-Week Range$2.21▼$6.44Volume345,524 shsAverage Volume905,319 shsMarket Capitalization$676.12 millionP/E RatioN/ADividend YieldN/APrice Target$10.00Consensus RatingHold Company OverviewCureVac N.V., a biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic vaccines, such as mRNA-based vaccine candidates CV2CoV, which is in Phase 1 clinical trial against SARS-CoV-2; CV7202 which is in Phase 1 clinical trial for the treatment of rabies; and CVSQIV to treat multivalent seasonal influenza; Flu SV mRNA fot treating nucleotides, single antigen seasonal influenza. The company develops CV8102, which is in Phase 1 clinical trial for treating melanoma and adenoidcystic carcinoma, as well as squamous cell cancer of skin, head, and neck; and CVGBM for treating cancer. CureVac N.V. was founded in 2000 and is headquartered in Tübingen, Germany.Read More… Notice: Major payout due November 19th - are you on the list? (Ad)On Tuesday, November 19, 2024 smart investors will collect their share of a $1.2 billion windfall... It's part of a unique strategy which has nothing to do with risky investments like options, cryptos or forex. And while it might sound crazy...Click here for the ticker >>> CureVac Stock Analysis - MarketRank™See Top Rated MarketRank™ Stocks75th Percentile Overall ScoreCVAC MarketRank™: CureVac scored higher than 75% of companies evaluated by MarketBeat, and ranked 307th out of 994 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.1 / 5Analyst RatingHold Consensus RatingCureVac has received a consensus rating of Hold. The company's average rating score is 2.25, and is based on 1 buy rating, 3 hold ratings, and no sell ratings.Amount of Analyst CoverageCureVac has only been the subject of 1 research reports in the past 90 days.Read more about CureVac's stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for CureVac are expected to decrease in the coming year, from $0.05 to ($0.39) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of CureVac is -2.27, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of CureVac is -2.27, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Growth RatioCureVac has a PEG Ratio of 2.19. PEG Ratios above 1 indicate that a company could be overvalued.Price to Book Value per Share RatioCureVac has a P/B Ratio of 1.21. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about CureVac's valuation and earnings. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted5.88% of the float of CureVac has been sold short.Short Interest Ratio / Days to CoverCureVac has a short interest ratio ("days to cover") of 7.2.Change versus previous monthShort interest in CureVac has recently decreased by 0.54%, indicating that investor sentiment is improving. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldCureVac does not currently pay a dividend.Dividend GrowthCureVac does not have a long track record of dividend growth. Sustainability and ESG4.9 / 5Environmental Score-1.86 Percentage of Shares Shorted5.88% of the float of CureVac has been sold short.Short Interest Ratio / Days to CoverCureVac has a short interest ratio ("days to cover") of 7.2.Change versus previous monthShort interest in CureVac has recently decreased by 0.54%, indicating that investor sentiment is improving. News and Social Media3.4 / 5News Sentiment1.10 News SentimentCureVac has a news sentiment score of 1.10. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.55 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for CureVac this week, compared to 2 articles on an average week.Search InterestOnly 3 people have searched for CVAC on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.MarketBeat Follows5 people have added CureVac to their MarketBeat watchlist in the last 30 days. Company Ownership0.0 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, CureVac insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 2.15% of the stock of CureVac is held by insiders.Percentage Held by InstitutionsOnly 17.26% of the stock of CureVac is held by institutions.Read more about CureVac's insider trading history. Receive CVAC Stock News and Ratings via Email Sign-up to receive the latest news and ratings for CureVac and its competitors with MarketBeat's FREE daily newsletter. Email Address CVAC Stock News HeadlinesInnovation Pharmaceuticals (OTCMKTS:IPIX) vs. CureVac (NASDAQ:CVAC) Financial ContrastOctober 6 at 1:25 AM | americanbankingnews.comCureVac N.V.'s (NASDAQ:CVAC) top owners are individual investors with 35% stake, while 31% is held by private equity firmsOctober 1, 2024 | finance.yahoo.comWar on Elon Escalates… Elon Musk, the guy slated to become the world’s first trillionaire by 2027, has publicly called for the adoption of this technology for decades. By doing so he has put himself in the crosshairs of an ideological war with the global elites. And yet, while this new technology threatens their wealth and power, it could be transformational for both the U.S. economy and your wealth.October 6, 2024 | Porter & Company (Ad)CureVac (NASDAQ:CVAC) Shares Down 3.3% September 28, 2024 | americanbankingnews.comCureVac's cancer vaccine shows promise in early trialSeptember 15, 2024 | uk.investing.comCureVac’s Promising Cancer Vaccine Candidate CVGBM Elicits Buy RatingSeptember 13, 2024 | markets.businessinsider.comEQS-News: CureVac’s CVGBM Cancer Vaccine Induces Promising Immune Responses in Phase 1 Study in Glioblastoma Presented at the ESMO 2024 CongressSeptember 13, 2024 | markets.businessinsider.comEQS-News: CureVac Partner GSK Announces Positive Phase 2 Data from Seasonal Influenza mRNA Vaccine ProgramSeptember 13, 2024 | markets.businessinsider.comSee More Headlines CVAC Stock Analysis - Frequently Asked Questions How have CVAC shares performed this year? CureVac's stock was trading at $4.21 at the start of the year. Since then, CVAC stock has decreased by 28.3% and is now trading at $3.02. View the best growth stocks for 2024 here. How were CureVac's earnings last quarter? CureVac (NASDAQ:CVAC) announced its quarterly earnings results on Thursday, August, 15th. The company reported ($0.34) EPS for the quarter, missing the consensus estimate of ($0.28) by $0.06. The business had revenue of $15.55 million for the quarter, compared to analysts' expectations of $10.07 million. CureVac had a negative net margin of 422.66% and a negative trailing twelve-month return on equity of 57.18%. When did CureVac IPO? CureVac (CVAC) raised $200 million in an initial public offering on Friday, August 14th 2020. The company issued 13,300,000 shares at a price of $14.00-$16.00 per share. BofA Securities, Jefferies and Credit Suisse served as the underwriters for the IPO and Berenberg and Kempen were co-managers. How do I buy shares of CureVac? Shares of CVAC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of CureVac own? Based on aggregate information from My MarketBeat watchlists, some other companies that CureVac investors own include Moderna (MRNA), Tesla (TSLA), Novavax (NVAX), Inovio Pharmaceuticals (INO), Gilead Sciences (GILD), Pfizer (PFE) and Company Calendar Last Earnings8/15/2024Today10/05/2024Next Earnings (Estimated)11/12/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biotechnology Sub-IndustryN/A Current SymbolNASDAQ:CVAC CUSIPN/A CIK1809122 Webwww.curevac.com Phone49-70-71988-30Fax49-7071-9883Employees999Year FoundedN/APrice Target and Rating Average Stock Price Target$10.00 High Stock Price Target$16.00 Low Stock Price Target$4.00 Potential Upside/Downside+231.1%Consensus RatingHold Rating Score (0-4)2.25 Research Coverage4 Analysts Profitability EPS (Most Recent Fiscal Year)($1.33) Trailing P/E RatioN/A Forward P/E Ratio60.40 P/E Growth2.19Net Income$-281,580,000.00 Net Margins-422.66% Pretax Margin-419.62% Return on Equity-57.18% Return on Assets-38.60% Debt Debt-to-Equity Ratio0.09 Current Ratio2.29 Quick Ratio2.28 Sales & Book Value Annual Sales$65.86 million Price / Sales10.27 Cash FlowN/A Price / Cash FlowN/A Book Value$2.50 per share Price / Book1.21Miscellaneous Outstanding Shares223,880,000Free Float219,067,000Market Cap$676.12 million OptionableOptionable Beta2.62 Ten Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free Report This page (NASDAQ:CVAC) was last updated on 10/6/2024 by MarketBeat.com Staff From Our PartnersElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredHow a $200,000 Mistake Unlocked a $118 Billion Gold TreasureThe window of opportunity on this gold stock is closing fast. Once word gets out, it may be too late.Monument Traders Alliance | Sponsored⭕ [URGENT] Buy Alert just triggeredMy absolute favorite stock just hit a critical "buy now" trigger price.Behind the Markets | SponsoredHow much money are you leaving on the table from the stocks you already own?Charles Payne here, and I want to let you in on a time-tested trading method that can be used to generate cash...Unstoppable Prosperity | SponsoredSell NVDA Now?Guess who's selling NVDA next The most successful hedge fund in history quietly sold 500,000 shares. Here's...Chaikin Analytics | SponsoredEx WH Advisor Who Predicted Biden Leaving Race Makes Startling New PredictionFormer advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… ...Paradigm Press | SponsoredWar on Elon Escalates… Elon Musk, the guy slated to become the world’s first trillionaire by 2027, has publicly called for the adopti...Porter & Company | SponsoredGolden Equation: Volatility = OpportunityWhen the market swings wildly, most investors panic… But it doesn't have to be this way. You see, when t...Prosper Trading Academy | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding CureVac Please log in to your account or sign up in order to add this asset to your watchlist. Share CureVac With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.